Dyne Therapeutics (DYN) Reiterated at Overweight by Cantor Fitzgerald on Ph1/2 Data Release
September 30, 2026 7:00 AM
Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Dyne Therapeutics (NASDAQ: DYN).The analyst commented, "Dyne released additional 1-year ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
